Aevi Genomic Medicine Inc (NASDAQ:GNMX) has been given a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Analysts have set a one year consensus price target of $1.00 for the company and are forecasting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also given Aevi Genomic Medicine an industry rank of 142 out of 255 based on the ratings given to its competitors.
Several research firms have commented on GNMX. JMP Securities cut shares of Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 3rd. ValuEngine cut shares of Aevi Genomic Medicine from a “hold” rating to a “sell” rating in a research note on Thursday, December 20th.
A hedge fund recently bought a new stake in Aevi Genomic Medicine stock. Bridgeway Capital Management Inc. acquired a new position in Aevi Genomic Medicine Inc (NASDAQ:GNMX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 223,500 shares of the biotechnology company’s stock, valued at approximately $275,000. Bridgeway Capital Management Inc. owned about 0.35% of Aevi Genomic Medicine at the end of the most recent reporting period. Institutional investors and hedge funds own 19.18% of the company’s stock.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Further Reading: What is Call Option Volume?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.